6846.Two
6846.TWO is a pharmaceutical company that develops, produces, and sells a range of pharmaceutical products, primarily generating revenue through the sale of these products to healthcare providers and consumers.
Business. 6846.TWO is a pharmaceutical company that develops, produces, and sells a range of pharmaceutical products, primarily generating revenue through the sale of these products to healthcare providers and consumers.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6846.TWO is a pharmaceutical company that develops, produces, and sells a range of pharmaceutical products, primarily generating revenue through the sale of these products to healthcare providers and consumers.
The company maintains a market price of TWD 68.3, with a market capitalization of TWD 1.85 billion, and a price-to-earnings ratio of 12.69, which is relatively low compared to the industry median. The price-to-book ratio of 1.89 suggests that the company is trading at a premium to its book value, but not excessively so. The enterprise value to EBITDA ratio of 14.64 and the enterprise value to revenue ratio of 3.02 indicate a moderate valuation relative to earnings and revenue, respectively.
In terms of profitability, the company's return on equity of 14.87% and return on assets of 6.9% are both above the industry median, suggesting strong returns relative to its equity and asset base. The gross profit margin of 48.07% and operating margin of 20.61% are also favorable, indicating efficient cost management and strong pricing power.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The company's free cash flow is negative at TWD -311.26 million, which is a concern given the high capital expenditures of TWD -395.08 million. This suggests that the company is reinvesting heavily in its operations, but at the expense of immediate cash generation.
Looking ahead, the company is expected to see a modest increase in revenue, with a projected growth rate of 2.5% for the current fiscal year and 3.0% for the next fiscal year. This growth is driven by the expansion of its product portfolio and increased market penetration in existing markets. However, the company's high debt-to-equity ratio of 0.94 and the negative net cash position after subtracting total debt indicate potential liquidity constraints. The company's liquidity risk is rated as medium, and the risk of dilution is low, although the negative free cash flow could necessitate future equity or debt financing.
Recent filings and transcripts indicate that the company is focusing on expanding its R&D capabilities and entering new markets. The company has also been investing in digital transformation to improve operational efficiency. These initiatives are expected to drive long-term growth but may require significant upfront investment.
The company's risk assessment highlights several key flags, including the negative net cash position after subtracting total debt. This could limit the company's ability to invest in growth opportunities or withstand economic downturns. The company's liquidity risk is rated as medium, and while the dilution risk is currently low, the negative free cash flow and high capital expenditures could change this outlook if the company needs to raise additional capital.
- The company has a strong return on equity and return on assets, indicating efficient use of capital and assets.
- The company's valuation metrics, including price-to-earnings and enterprise value to EBITDA, are relatively low, suggesting potential undervaluation.
- The company's free cash flow is negative, and capital expenditures are high, indicating significant reinvestment in operations.
- The company's revenue is concentrated in a single segment, increasing exposure to market-specific risks.
- The company's liquidity risk is medium, and the negative net cash position after subtracting total debt is a concern.
- The company is investing in R&D and digital transformation to drive long-term growth.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 6846.TWO Market data — financials · 2026-05-27